Revolutionizing T-Cells for Solid Tumor Cell Therapies, Gary Lee, CSO, Lyell Immunopharma
Synopsis:
Gary Lee, Ph.D. is the CSO of Lyell Immunopharma, a T-cell reprogramming company dedicated to developing cell therapies for patients with solid tumors. A chemical engineer by training, Gary has been working in the gene therapy field for 20+ years. He discusses how he’s observed the cell therapy space evolve over the last couple of decades. He talks about the work his team is doing to develop effective cell-based therapies for solid tumor cancers and where they are from a development and team-building perspective. He also provides his perspective on opportunities he sees for future technology across the cell therapy landscape.
Biography:
Gary Lee, Ph.D., has served as Lyell’s Chief Scientific Officer since January 2022. Dr. Lee is a veteran biotech executive with decades of experience leading cell and gene therapy programs for human applications. From October 2018 to January 2022, Dr. Lee was the Chief Scientific Officer at Senti Bio. From August 2005 to October 2018, Dr. Lee held positions of increasing scientific and leadership responsibility at Sangamo Therapeutics, including last as the Vice President of Cell Therapy. Dr. Lee earned his Ph.D. in Chemical Engineering from the University of California, Berkeley, and his B.S. in Chemical Engineering from the California Institute of Technology.